KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Phase 2 Active not recruiting 120 enrolled Kyverna Therapeutics

RandomizedParallel-groupOpen-labelTreatment

Summary

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis

Timeline

Start: 2024-09-20
Primary completion: 2027-04
Completion: 2029-01

Publications

Background Silva BA, Miglietta E, Ferrari CC. Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients. Mult Scler Relat Disord. 2021 May;50:102845. doi: 10.1016/j.msard.2021.102845. Epub 2021 Feb 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KYV-101	Cell therapy	—	—
Background	CYC	Unknown	—	—
Background	FLU	Unknown	—	—

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Summary

Timeline

Publications

Drugs

Indications